Original Article
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
N Engl J Med 2005; 353:2219-2228November 24, 2005
- Abstract
Background
Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable.
Methods
We conducted a 24-week randomized, open-label, noninferiority trial comparing oral mycophenolate mofetil (initial dose, 1000 mg per day, increased to 3000 mg per day) with monthly intravenous cyclophosphamide (0.5 g per square meter of body-surface area, increased to 1.0 g per square meter) as induction therapy for active lupus nephritis. A change to the alternative regimen was allowed at 12 weeks in patients who did not have an early response. The study protocol specified adjunctive care and the use and tapering of corticosteroids. The primary end point was complete remission at 24 weeks (normalization of abnormal renal measurements and maintenance of baseline normal measurements). A secondary end point was partial remission at 24 weeks.
Results
Of 140 patients recruited, 71 were randomly assigned to receive mycophenolate mofetil and 69 were randomly assigned to receive cyclophosphamide. At 12 weeks, 56 patients receiving mycophenolate mofetil and 42 receiving cyclophosphamide had satisfactory early responses. In the intention-to-treat analysis, 16 of the 71 patients (22.5 percent) receiving mycophenolate mofetil and 4 of the 69 patients receiving cyclophosphamide (5.8 percent) had complete remission, for an absolute difference of 16.7 percentage points (95 percent confidence interval, 5.6 to 27.9 percentage points; P=0.005), meeting the prespecified criteria for noninferiority and demonstrating the superiority of mycophenolate mofetil to cyclophosphamide. Partial remission occurred in 21 of the 71 patients (29.6 percent) and 17 of the 69 patients (24.6 percent), respectively (P=0.51). Three patients assigned to cyclophosphamide died, two during protocol therapy. Fewer severe infections and hospitalizations but more diarrhea occurred among those receiving mycophenolate.
Conclusions
In this 24-week trial, mycophenolate mofetil was more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis and had a more favorable safety profile.
Media in This Article
Figure 1
Enrollment of Patients, Treatment Assignments, and Outcomes, According to the Intention-to-Treat Analysis.Table 1
Characteristics of Patients at the Beginning of Induction Therapy.Article Activity
- Article
Intravenous cyclophosphamide has been the standard of care for treating severe lupus glomerulonephritis1; however, its use is limited by potentially severe toxic effects including bone marrow suppression, hemorrhagic cystitis, opportunistic infections, malignant diseases, and premature gonadal failure.2 Clinical trials of treatment with intermittent intravenous cyclophosphamide combined with corticosteroids show greater long-term renal survival but not overall survival, as compared with treatment with corticosteroids alone.3-6 Furthermore, failure to achieve remission, which is associated with an increased rate of progression to renal failure, is reported in 18 to 57 percent of patients who received cyclophosphamide.7-10
Mycophenolate mofetil, an immunosuppressive agent approved for the prevention of transplant rejection, has been used in patients with lupus nephritis that is refractory to cyclophosphamide and in patients who cannot tolerate cyclophosphamide.11-14 Pilot studies of mycophenolate mofetil were uncontrolled and often appeared to be biased toward a poor outcome, given patients' history of therapeutic failures.
In the present study, the efficacy, safety, and tolerability of oral mycophenolate mofetil plus corticosteroids were compared with those of intravenous cyclophosphamide plus corticosteroids for inducing remission of active lupus nephritis in an open-label, randomized, noninferiority study designed to include crossover to the alternative regimen among patients who did not have an early response to the study therapy.
Methods
Study Design
We conducted a multicenter, randomized, open-label, controlled trial from December 1999 (when the first patient enrolled underwent randomization) through October 2003 (completion of the study). Eligibility criteria included systemic lupus erythematosus meeting four classification criteria of the American College of Rheumatology15; renal biopsy documenting lupus nephritis according to the classification of the World Health Organization as proliferative glomerulonephritis class III (focal), IV (diffuse), or V (membranous); and clinical activity as defined by one or more of the following: incident decrease in renal function (serum creatinine, >1.0 mg per deciliter [88.4 μmol per liter]), proteinuria (defined as more than 500 mg of protein in a 24-hour urine specimen), microscopic hematuria (defined as >5 red cells per high power-field) or the presence of cellular casts, increasing proteinuria with rising levels of serum creatinine, active urine sediment (hematuria or cellular casts), or serologic abnormality (anti-DNA antibodies or hypocomplementemia). To ensure that patients whose biopsy specimens indicated less severe disease required immunosuppressive therapy, those with class III or V lupus nephritis were required to have a serum creatinine level greater than 1.0 mg per deciliter or proteinuria greater than 2 g in a 24-hour urine specimen. Exclusion criteria were creatinine clearance of less than 30 ml per minute, serum creatinine on repeated testing greater than 3.0 mg per deciliter (265.2 μmol per liter), severe coexisting conditions precluding immunosuppressive therapy or conditions requiring intravenous antibiotic therapy, prior treatment with mycophenolate mofetil, treatment with intravenous cyclophosphamide within the past 12 months, monoclonal antibody therapy within the past 30 days, or pregnancy or lactation.
Institutional review boards at each study center approved the study design. Because therapeutic responses may differ depending on the pattern of renal histologic features, the patients were stratified according to renal biopsy as having proliferative glomerulonephritis (class III or IV), as compared with membranous glomerulonephritis (class V). Permuted blocks of patients of variable size (two through six) were used within each group. Treatment was assigned at a central site with the use of sealed envelopes. All patients gave written, informed consent before undergoing randomization.
Treatment Protocol
Mycophenolate mofetil was initiated at a dose of 500 mg twice daily, and the dose was increased to 750 mg twice daily at week 2 and advanced weekly to a maximum dose of 1000 mg three times daily unless the white-cell count fell below 3000 per cubic millimeter. Intravenous cyclophosphamide was given as monthly pulses according to a protocol of the National Institutes of Health (NIH).3 Dosage was modified on the basis of the nadir white-cell count of 2500 cells or less per square meter of body-surface area at 7 to 10 days after the infusion. Patients received prednisone at a dose of 1 mg per kilogram of body weight per day, with tapering by 10 to 20 percent at one-week or two-week intervals, on the basis of clinical improvement. The new appearance or worsening of manifestations of extrarenal disease could be treated with one three-day pulse of intravenous methylprednisolone or increased doses of corticosteroids to a maximum of 2 mg per kilogram per day. Standard laboratory assessments were performed locally at entry into the study and at monthly intervals, to assess the efficacy and toxic effects of the study drugs.
Study End Points
The primary end point was complete remission at 24 weeks, defined as the return to within 10 percent of normal values of serum creatinine levels, proteinuria, and urine sediment. A secondary end point was partial remission at 24 weeks, defined as improvement of 50 percent in all abnormal renal measurements, without worsening (within 10 percent) of any measurement. Additional secondary end points included changes in renal function, complement components, anti–double-stranded DNA (dsDNA) antibody titers, and serum albumin levels.
As a safety measure, assessment of the therapeutic efficacy of the treatment after 12 weeks identified patients who did not have an early response, defined as an improvement of 30 percent in at least two measures of renal function (serum creatinine, proteinuria, or urine sediment) if all three measures were abnormal at entry into the study, or an improvement of 30 percent in one measure if one or two others were abnormal, provided no measures that were normal at baseline became abnormal. Treatment failure was defined as a condition requiring higher doses of corticosteroids for disease control, failure to meet the criteria for an early response, or failure to reach complete or partial remission at 24 weeks. Toxic effects requiring discontinuation of the study drug or withdrawal from the study for any other reason was also considered treatment failure.
Statistical Analysis
The protocol was designed as a noninferiority trial16 to demonstrate that mycophenolate mofetil is at least as efficacious as intravenous cyclophosphamide as induction therapy for active lupus nephritis. The criterion for establishing noninferiority was that the lower bound of the two-sided 95 percent confidence interval for the difference in rates of complete remission (mycophenolate mofetil minus intravenous cyclophosphamide) must exceed the predefined noninferiority margin (minus 10 percent). To determine the size of the sample, we assumed a rate of expected complete remission at 24 weeks in the cyclophosphamide group of 30 percent. On the basis of anecdotal success with mycophenolate mofetil in cyclophosphamide-resistant nephritis, the likelihood that mycophenolate mofetil would be even more efficacious as primary therapy, and the drug's low reported incidence of serious toxic effects,11,12 the rate of complete remission with mycophenolate mofetil was expected to be between 40 and 45 percent. Under these assumptions, a sample size of 70 patients in each of the two treatment groups was calculated to yield 80 percent power to conclude that mycophenolate mofetil was not inferior to intravenous cyclophosphamide with a one-sided alpha level of 0.025.
The analysis was based on the intention-to-treat principle, regardless of treatment adherence. The proportions of patients in the two groups who had complete remission and partial remission at 24 weeks were compared with the use of Pearson's chi-square test. In our primary analysis, patients for whom outcome data were missing because of loss to follow-up were assumed not to have had a response. The data were also analyzed by including only patients for whom outcome information was available. Differences in the baseline characteristics between the two groups and changes from baseline at each time point were evaluated with the use of the two-sample t-test for continuous variables and the chi-square test for categorical variables. Times to event for the end points of partial and complete remission were analyzed with the use of the Cox proportional-hazards model. All reported P values are two-sided. No interim analyses were performed.
The study was designed as a 24-week induction trial with no protocol specified for maintenance therapy. Data were not collected prospectively with regard to post-induction outcomes or therapy. Subsequently, the study sites were asked to provide laboratory data, data on maintenance therapy, and dates of nephritis flares, renal failure, and death at years 1 and 2 after randomization and at the last follow-up visit with the use of a standard database.
This investigator-generated study was designed and conducted by the authors (with other site investigators), and the data were analyzed solely by the authors, who hold the data and prepared the manuscript. Roche Laboratories provided a supplemental grant but had no role in the design and conduct of the study or in the analysis of the results.
Results
Of 140 patients recruited at 19 study sites, 71 were assigned to mycophenolate mofetil and 69 to intravenous cyclophosphamide. The characteristics of the patients in the two groups were similar at baseline (Table 1Table 1
Characteristics of Patients at the Beginning of Induction Therapy.).Study End Points
At 12 weeks, 56 patients in the mycophenolate group and 42 in the cyclophosphamide group had responses that met the criteria for an early response (Figure 1Figure 1
Enrollment of Patients, Treatment Assignments, and Outcomes, According to the Intention-to-Treat Analysis.). Seven patients (9.9 percent) assigned to mycophenolate mofetil and 15 patients (21.7 percent) assigned to cyclophosphamide were lost to follow-up. In the intention-to-treat analysis, assuming that those lost to follow-up did not have an early response, 16 of 71 patients in the mycophenolate group (22.5 percent) and 4 of the 69 patients in the intravenous cyclophosphamide group (5.8 percent) had complete remission, yielding an absolute treatment difference of 16.7 percentage points (95 percent confidence interval, 5.6 to 27.9 percentage points; P=0.005). Since the lower bound of the confidence interval not only exceeds the predetermined noninferiority margin (minus 10 percent) but also exceeds 0 percent, both the noninferiority and the superiority of mycophenolate mofetil to intravenous cyclophosphamide are demonstrated. When patients for whom outcome data were missing were excluded from the analysis, 16 patients (25.0 percent) of 64 in the mycophenolate group had complete responses, and 4 patients (7.4 percent) of 54 in the cyclophosphamide group had complete responses, a difference of 17.6 percent (95 percent confidence interval, 4.9 to 30.3 percent; P=0.01).Partial remission occurred in 21 patients (29.6 percent) in the mycophenolate mofetil group and 17 patients (24.6 percent) in the cyclophosphamide group in the intention-to-treat analysis (P=0.51). When these totals are combined, 37 patients (52.1 percent) of the 71 assigned to mycophenolate mofetil and 21 patients (30.4 percent) of the 69 assigned to cyclophosphamide had either complete or partial remission (P=0.009). Similar results were obtained after patients lost to follow-up were excluded from the analysis.
Patients in whom treatment failed included all those without complete or partial remission at 24 weeks, plus those who stopped treatment for any reason, yielding failure rates of 34 of 71 (47.9 percent) in the mycophenolate mofetil group, as compared with 48 of 69 in the cyclophosphamide group (69.6 percent, P=0.01) (Figure 1). At 24 weeks, the differences between the two groups with respect to levels of serum creatinine, proteinuria, urine sediment (red and white cells), serum albumin, complement C3 and C4, and anti-dsDNA were not significant (Table 2Table 2
Laboratory Values for Primary and Secondary End Points.).Rates of Crossover and Withdrawal
Twenty-four patients were withdrawn from the study, 9 in the mycophenolate mofetil group and 15 in the cyclophosphamide group (Figure 1). Of the nine in the mycophenolate mofetil group, five were withdrawn within 3 to 60 days after randomization because of the increasing severity of disease. One of these patients was withdrawn because of noncompliance with the protocol; two of the eight patients who did not have an early response refused to change therapy to cyclophosphamide; and one withdrew because of a generalized rash. Of the 15 patients in the cyclophosphamide group who withdrew, 3 patients refused treatment; 3 patients were withdrawn because of the severity of disease, 6 were withdrawn because of noncompliance, and 1 was withdrawn because lymphopenia developed. Two patients in this group were lost to follow-up.
Immunosuppressive Therapy
The mean maximal tolerated dose of mycophenolate mofetil was 2680 mg per day; of a total of 83 patients receiving mycophenolate mofetil (including those who crossed over to the therapy), 52 (63 percent) tolerated a dose of 3000 mg per day. Of the 69 patients in the intravenous cyclophosphamide group, 43 (62 percent) received six monthly doses of the drug. The cumulative dose of cyclophosphamide per patient after three months was 3430±355 mg, and after six months it was 7302±1695 mg.
The mean dose of cyclophosphamide among patients receiving treatment for 24 weeks was 909.7±176.0 mg per square meter of body-surface area per month among those who had a complete response, 746.0±174.4 mg among those who had a partial response, and 725.5±190.3 mg among those who had no response. The use of prednisone therapy was similar in the two groups; patients in the mycophenolate mofetil group received mean doses of prednisone at baseline, week 12, and week 24 of 47.8±19.0 mg per day, 24.1±16.4 mg, and 12.9±11.0 mg, respectively. In comparison, patients in the cyclophosphamide group received mean doses at these time points of 49.5±20.2 mg per day, 23.5±15.4 mg, and 14.1±11.6 mg, respectively (P=0.67, P=0.81, and P=0.60, respectively).
Adverse Events
There were two deaths in the cyclophosphamide group during treatment. One patient died from a cerebral hemorrhage within a week of receiving the first dose. The other patient received two doses, the second of which was delayed by sepsis; death occurred three weeks later and was related to active lupus and recurrent sepsis. A third patient assigned to cyclophosphamide declined therapy and died from pulmonary hemorrhage and renal failure at another hospital. There were no deaths during treatment in the mycophenolate mofetil group.
Infection and gastrointestinal side effects accounted for most of the adverse events (Table 3Table 3
Adverse Events.). Severe infections (pneumonia and lung abscess, necrotizing fasciitis, and gram-negative sepsis) occurred only with intravenous cyclophosphamide. Pyogenic infections were significantly less frequent among patients receiving mycophenolate mofetil than among those receiving cyclophosphamide (relative risk, 0.36; P=0.030). Hospitalizations for vomiting and dehydration occurred in five patients (a total of seven episodes) receiving cyclophosphamide. Diarrhea occurred more frequently with mycophenolate mofetil (15 patients) than with cyclophosphamide (2 patients); 3 patients in the mycophenolate mofetil group had chronic diarrhea, 1 of whom required a reduction in the dose to 1750 mg per day.Apparent drug-related hematologic toxic effects were uncommon. Incident neutropenia alone was responsible for a reduction in the dose of cyclophosphamide at only eight infusions among six patients. Baseline lymphopenia was present in 22 patients in the mycophenolate mofetil group and 15 patients in the cyclophosphamide group; in 13 patients and 2 patients, respectively, the lymphopenia was resolved. Herpes simplex developed in four patients with lymphopenia in the cyclophosphamide group and in two patients with lymphopenia in the mycophenolate mofetil group, both of them within one week of entry into the study. One patient treated with mycophenolate mofetil had an extensive rash that recurred with rechallenge. Menstrual irregularities occurred in 8 patients receiving mycophenolate mofetil, as compared with 11 patients receiving cyclophosphamide, 2 of whom had irreversible amenorrhea.
After induction therapy, the subsequent risks of renal flare, renal failure, and death on the basis of the initial induction-treatment assignment were examined with the use of a survival analysis of data collected after completion of the study protocol (Table 4Table 4
Outcomes during Follow-up after Induction Therapy.). Although data on laboratory values and maintenance therapy after induction were not always available for individual patients, the duration of follow-up was similar in the two groups (36.2±16.9 months in the mycophenolate mofetil group vs. 37.2±16.9 months in the intravenous cyclophosphamide group, P=0.72). Renal failure and death were twice as frequent among patients in the cyclophosphamide group, as compared with those in the mycophenolate mofetil group, but the number of events was small and was not statistically significant.Discussion
Despite the general acceptance of cyclophosphamide as the standard of care in lupus nephritis, serious toxic effects and imperfect efficacy have led to the search for alternative treatments. On the basis of anecdotal reports of success with mycophenolate mofetil in patients with lupus nephritis at high risk for poor outcomes, we hypothesized that mycophenolate mofetil would have an efficacy equivalent to that of intravenous cyclophosphamide in inducing remission of active nephritis, with fewer toxic effects and better acceptance by patients.
Before our trial was completed, two randomized studies comparing mycophenolate mofetil with cyclophosphamide for lupus nephritis were reported. Chan et al. reported on a 12-month study involving 42 patients with class IV nephritis in which mycophenolate mofetil was as effective as oral cyclophosphamide in inducing remission. In their study, the rate of infectious complications was similar in the two treatment groups, but only patients treated with cyclophosphamide had amenorrhea, alopecia, or leucopenia, or died.17 Hu et al. reported on 46 patients with class IV nephritis and concluded that six months of mycophenolate mofetil was more effective than intravenous cyclophosphamide in reducing proteinuria, hematuria, and autoantibody production.18
In our short-term study, the toxicity and tolerability profile of mycophenolate mofetil compared favorably with that of cyclophosphamide. Although upper gastrointestinal symptoms were common in the two groups, in the mycophenolate mofetil group the symptoms tended to be mild and self-limited, whereas in the intravenous cyclophosphamide group dehydration following treatment necessitated seven hospitalizations. Our findings are consistent with those in other studies; Mok and Lai noted that gastrointestinal intolerance was the most common side effect of mycophenolate mofetil but rarely led to withdrawal of the drug.19 The good tolerance among our patients may have been due to the regimen of gradual dose increases. Serious infections were less common with mycophenolate mofetil, which was similar to the findings of Hu et al.18 and of Chan et al.17
Our prospective controlled study was relatively large and involved a heterogeneous cohort, including patients from 19 academic and private-practice centers in the United States. Fifty-six percent of the patients were black, a subgroup often underrepresented in clinical trials but constituting a majority among Americans with lupus. Race was self-determined. Black race, minority ethnic background, and low socioeconomic status are associated with poor outcome — an outcome not mitigated by cyclophosphamide therapy.20-24 Therapeutic success in our study, in which high-risk patients were the majority, may be related to the high target dose of 3 g per day of mycophenolate mofetil. This regimen was based on transplantation data suggesting that black patients require higher doses of this agent.25,26
A limitation of our study is that treatment assignment was not blinded. Although this could lead to potential bias in patient recruitment and in the interpretation of results, the marked differences in the side-effect profiles of the two drugs would probably make true blinding difficult. Potential bias was minimized by selecting a primary end point with the use of objective laboratory measures. Although the early crossover design was chosen for safety, it may have led to a premature designation of treatment failure. In recent reports, the average time to remission with cyclophosphamide is 10 months.9,27 Our low response rate with cyclophosphamide may reflect an inability to achieve the recommended NIH protocol dosing; doses were regulated on the basis of toxic effects, primarily gastrointestinal symptoms. The trend toward better response with higher doses of cyclophosphamide highlights the association between efficacy and tolerability.
Another limitation of our study is its short duration and the restriction to induction therapy. Long-term experience in clinical trials using intravenous cyclophosphamide shows a relapse rate of up to 45 percent in patients with proliferative lupus nephritis, despite a complete clinical response to induction therapy.28 Furthermore, the type of maintenance therapy after successful intravenous cyclophosphamide appears to be important; Contreras et al. found the composite end point of death or chronic renal failure and the rate of relapse-free survival to be significantly higher with mycophenolate mofetil than with cyclophosphamide.29 Hospitalizations, amenorrhea, infections, and upper gastrointestinal symptoms were also significantly less frequent with mycophenolate mofetil than with cyclophosphamide. In contrast to the study by Contreras et al., an interim report by Chan et al. suggested an increased rate of flare associated with low-dose mycophenolate mofetil maintenance, as compared with azathioprine.30 The long-term follow-up (median, 63 months) in the study by Chan et al. showed a similar rate of renal relapse in both treatment groups with more gradual tapering of the maintenance dose of mycophenolate mofetil31 than in their initial study.17
Alternatives to cyclophosphamide and mycophenolate mofetil have been proposed, in particular maintenance with azathioprine.29,32 Cost–benefit considerations are important. Despite the higher cost of mycophenolate mofetil, as compared with intravenous cyclophosphamide, there are additional costs associated with cyclophosphamide infusion, including reimbursement for the infusion unit and the cost for antiemetic agents, mesna, and leuprolide. Thus, the actual cost of cyclophosphamide therapy may surpass that of mycophenolate mofetil.
In summary, induction therapy with mycophenolate mofetil was superior to intravenous cyclophosphamide in inducing complete remission of lupus nephritis in this study. Mycophenolate mofetil appeared to be better tolerated than cyclophosphamide. Unresolved issues include determining the flare rate after induction with mycophenolate mofetil, as compared with that for cyclophosphamide, and determining the appropriate dose and duration of mycophenolate mofetil maintenance therapy.
Supported by a grant from the Food and Drug Administration's Orphan Products Development program and a supplemental grant from Roche Laboratories.
Dr. Ginzler reports having received consulting fees from Aspreva Pharmaceuticals, Genentech, Bristol-Myers Squibb, and La Jolla Pharmaceuticals; lecture fees from International Medical Press, Aspreva Pharmaceuticals, and Pfizer; and grant support from Genelabs Technologies, Amgen, Roche Laboratories, Human Genome Sciences, Aspreva Pharmaceuticals, Genentech, and Bristol-Myers Squibb. Dr. Dooley reports having received consulting fees from Aspreva Pharmaceuticals, Genentech, and Teva Pharmaceuticals; lecture fees from Pfizer; and grant support from Genentech and Human Genome Sciences. Dr. Aranow reports having received grant support from Genelabs Technologies and Human Genome Sciences. Dr. Buyon reports having received consulting fees from Aspreva Pharmaceuticals, Amgen, Bristol-Myers Squibb, Eli Lilly, Genentech, Johnson & Johnson, La Jolla Pharmaceuticals, and Pfizer; and grant support from Prometheus Laboratories. Dr. Merrill reports having received consulting fees from Aspreva Pharmaceuticals, Bristol-Myers Squibb, Genentech, La Jolla Pharmaceuticals, Teva Pharmaceuticals, Otsuka, and Immunomedics; lecture fees from Aspreva and Genentech; and grant support from Human Genome Sciences, Amgen, Otsuka, and Bio-Rad. Dr. Petri reports having received consulting fees from Aspreva. Dr. Weisman reports having received consulting fees from Abbott, Prometheus Laboratories, Regeneron, Genentech, and Human Genome Sciences; lecture fees from Abbott, Amgen, Centocor, and Pfizer; and grant support from Amgen, Human Genome Sciences, Bio-Rad, Immunex, and Knoll/Abbott Pharmaceuticals. Dr. Appel reports having received consulting fees from Aspreva, Roche Laboratories, and La Jolla Pharmaceuticals; lecture fees from Aspreva, Roche, and Genentech; and grant support from Aspreva.
We are indebted to Karen Orloff for overall coordination of the study sites, and to Ann Rupel for assistance in the preparation of the manuscript.
Source Information
From the Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn (E.M.G., C.A.); the Department of Medicine, University of North Carolina, Chapel Hill (M.A.D.); the Division of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, N.Y. (M.Y.K.); Hospital for Joint Diseases of New York University School of Medicine, New York (J.B.); the Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City (J.T.M.); the Department of Medicine, Johns Hopkins School of Medicine, Baltimore (M.P.); the Medical University of South Carolina, Charleston (G.S.G.); Cedars–Sinai Medical Center, Los Angeles (D.J.W., M.H.W.); and the Division of Nephrology, Columbia University Medical Center, New York (G.B.A.).
Address reprint requests to Dr. Ginzler at the Division of Rheumatology, SUNY Downstate Medical Center, 450 Clarkson Ave., Box 42, Brooklyn, NY 11203, or at ellen.ginzler@downstate.edu.
The institutions and investigators participating in the study are listed in the Appendix.
Appendix
The following institutions and investigators enrolled patients in the study: SUNY Downstate Medical Center, Brooklyn, N.Y. — E. Ginzler, C. Aranow; Hospital for Joint Diseases at NYU Medical Center, New York — J. Buyon; University of North Carolina at Chapel Hill, Chapel Hill — M. Dooley; St. Luke's–Roosevelt Hospital, New York — J. Merrill; Oklahoma Medical Research Foundation, Oklahoma City — J. Merrill; Johns Hopkins University, Baltimore — M. Petri; Cedars–Sinai Medical Center, Los Angeles — D. Wallace, M. Weisman; Columbia University, New York — G. Appel, J. Radhakrishnan; Medical University of South Carolina, Charleston — G. Gilkeson; George Washington University, Washington, D.C. — A. Weinstein, R. Curiel; Washington Hospital Center, Washington, D.C. — A. Weinstein; Vanderbilt University, Nashville — N. Olsen; Louisiana State University, Shreveport — M. Hearth-Holmes; Cleveland MetroHealth Center, Cleveland — S. Ballou; Ohio State University, Columbus — L. Hebert; University of Chicago, Chicago — T. Utset; University of California at Los Angeles, Los Angeles — K. Kalunian, J. Grossman; Hospital for Special Surgery, New York — D. Erkan; Lahey Clinic, Burlington, Mass. — A. Schneebaum.
- References
References
1
Steinberg AD ,Steinberg SC . Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-950
CrossRef | Web of Science | Medline2
Boumpas DT ,Austin HA III ,Fessler BJ ,Balow JE ,Klippel JH ,Lockshin MD . Systemic lupus erythematosus: emerging concepts. Part I. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995;122:940-950
Web of Science | Medline3
Austin HA III ,Klippel JH ,Balow JE , et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619
Full Text | Web of Science | Medline4
Valeri A ,Radhakrishnan J ,Estes D , et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994;42:71-78
Web of Science | Medline5
Lehman TJ ,Sherry DD ,Wagner-Weiner L , et al. Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 1989;114:1055-1060
CrossRef | Web of Science | Medline6
Boumpas DT ,Austin HA III ,Vaughn EM , et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-745
CrossRef | Web of Science | Medline7
Korbet SM ,Lewis EJ ,Schwartz MM ,Reichlin M ,Evans J ,Rohde RD . Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000;35:904-914
CrossRef | Web of Science | Medline8
Gourley MF ,Austin HA III ,Scott D , et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996;125:549-557
Web of Science | Medline9
Ioannidis JPA ,Boki KA ,Katsorida EM , et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-264
CrossRef | Web of Science | Medline10
Mok CC ,Ying KY ,Tang S , et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004;50:2559-2568
CrossRef | Web of Science | Medline11
Dooley MA ,Cosio FG ,Nachman PH , et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999;10:833-839
Web of Science | Medline12
Gaubitz M ,Schorat A ,Schotte H ,Kern P ,Domschke W . Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999;8:731-736
CrossRef | Web of Science | Medline13
Kingdon EJ ,McLean AG ,Psimenou E , et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001;10:606-611
CrossRef | Web of Science | Medline14
Karim MY ,Alba P ,Cuadrado MJ , et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002;41:876-882
CrossRef | Web of Science | Medline15
Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725-1725
CrossRef | Web of Science | Medline16
Kim MY ,Buyon JP ,Petri M ,Skovron ML ,Shore RE . Equivalence trials in SLE research: issues to consider. Lupus 1999;8:620-626
CrossRef | Web of Science | Medline17
Chan TM ,Li FK ,Tang CSO , et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-1162
Full Text | Web of Science | Medline18
Hu W ,Liu Z ,Chen H , et al. Mycophenolate mofetil vs. cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002;115:705-709
Web of Science | Medline19
Mok CC ,Lai KN . Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis 2002;40:447-457
CrossRef | Web of Science | Medline20
Dooley MA ,Hogan S ,Jennette C ,Falk R . Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997;51:1188-1195
CrossRef | Web of Science | Medline21
Barr RG ,Seliger S ,Appel GB , et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003;18:2039-2046
CrossRef | Web of Science | Medline22
Velasquez X ,Verdejo U ,Massardo L , et al. Outcome of Chilean patients with lupus nephritis and response to intravenous cyclophosphamide. J Clin Rheumatol 2003;9:7-14
CrossRef | Web of Science | Medline23
Al Salloum AA . Cyclophosphamide therapy for lupus nephritis: poor survival in Arab children. Pediatr Nephrol 2003;18:357-361
Web of Science | Medline24
Alarcon GS ,McGwin G Jr ,Bastian HM , et al. Systemic lupus erythematosus in three ethnic groups. VII. Predictors of early mortality in the LUMINA cohort. Arthritis Rheum 2001;45:191-202[Erratum, Arthritis Rheum 2001;45:306.]
CrossRef | Web of Science | Medline25
Neylan JF . Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997;64:1277-1282
CrossRef | Web of Science | Medline26
Schweitzer EJ ,Yoon S ,Fink J , et al. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. Transplantation 1998;65:242-248
CrossRef | Web of Science | Medline27
Cortes-Hernandez J ,Ordi-Rios J ,Labrador M , et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003;12:287-296
CrossRef | Web of Science | Medline28
Illei GG ,Takada K ,Parkin D , et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002
CrossRef | Web of Science | Medline29
Contreras G ,Pardo V ,Leclercq B , et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-980
Full Text | Web of Science | Medline30
Chan TM ,Wong WS ,Lau CS , et al. Follow-up of patients with diffuse proliferative lupus nephritis treated with prednisolone and mycophenolate mofetil. J Am Soc Nephrol 2001;12:195A-195A abstract.31
Chan TM ,Tse KC ,Tang CSO ,Mok MY ,Li FK . Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-1084
CrossRef | Web of Science | Medline32
Houssiau FA ,Vasconcelos C ,D'Cruz D , et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from the long-term followup of the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-3940
CrossRef | Web of Science | Medline
- Citing Articles (211)
Citing Articles
1
James E. Balow. (2012) Glomerular disease: Perspectives on maintenance therapy in lupus nephritis. Nature Reviews Nephrology
CrossRef2
A. Rother, P. Glander, E. Vitt, D. Czock, N. Ahsen, V. W. Armstrong, M. Oellerich, K. Budde, R. Feneberg, B. Tönshoff, L. T. Weber. (2012) Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. European Journal of Clinical Pharmacology
CrossRef3
G. Ruiz-Irastorza, A. Danza, M. Khamashta. (2012) Glucocorticoid use and abuse in SLE. Rheumatology
CrossRef4
Fabien B Vincent, Eric F Morand, Fabienne Mackay. (2012) BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunology and Cell Biology
CrossRef5
Tung-Min Yu, Mie-Chin Wen, Chi-Yuan Li, Chi-Huang Cheng, Ming-Ju Wu, Cheng-Hsu Chen, Yi-Hsing Chen, Hao-Chung Ho, Kuo-Hsiung Shu. (2012) Impact of recurrent lupus nephritis on lupus kidney transplantation. Clinical Rheumatology
CrossRef6
M. Haubitz. (2012) Lupusnephritis. Der Nephrologe 7:1, 63-74
CrossRef7
Mindy S. Lo, George C. Tsokos. (2012) Treatment of systemic lupus erythematosus: new advances in targeted therapy. Annals of the New York Academy of Sciencesno-no
CrossRef8
Frédéric A Houssiau. (2012) Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Research & Therapy 14:1, 202
CrossRef9
William L. Whittier, Edmund J. Lewis. 2012. Lupus nephritis. , 244-250.
CrossRef10
S. M. Korbet, E. J. Lewis, . (2011) Complete remission in severe lupus nephritis: assessing the rate of loss in proteinuria. Nephrology Dialysis Transplantation
CrossRef11
Tania C González-Rivera, Joseph McCune. (2011) Mycophenolate mofetil for the induction and maintenance treatment of lupus nephritis. Immunotherapy 3:12, 1431-1440
CrossRef12
Alexandre Karras. (2011) Atteinte rénale du lupus érythémateux disséminé. La Presse Médicale
CrossRef13
Houssiau, Frédéric A., . (2011) Toward Better Treatment for Lupus Nephritis. New England Journal of Medicine 365:20, 1929-1930
Full Text14
Dooley, Mary Anne, Jayne, David, Ginzler, Ellen M., Isenberg, David, Olsen, Nancy J., Wofsy, David, Eitner, Frank, Appel, Gerald B., Contreras, Gabriel, Lisk, Laura, Solomons, Neil, . (2011) Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. New England Journal of Medicine 365:20, 1886-1895
Full Text15
Keiko Uchida, Kosaku Nitta. (2011) Recent advances in the treatment of lupus nephritis. Clinical and Experimental Nephrology
CrossRef16
A. Alsuwaida, S. Husain, M. Alghonaim, N. AlOudah, J. Alwakeel, A. ullah, H. Kfoury. (2011) Strategy for second kidney biopsy in patients with lupus nephritis. Nephrology Dialysis Transplantation
CrossRef17
X. Li, H. Ren, Q. Zhang, W. Zhang, X. Wu, Y. Xu, P. Shen, N. Chen. (2011) Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrology Dialysis Transplantation
CrossRef18
Maria Dall’Era. (2011) Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Current Opinion in Rheumatology 23:5, 454-458
CrossRef19
R. A. Hickman, C. Gordon. (2011) Causes and management of infertility in systemic lupus erythematosus. Rheumatology 50:9, 1551-1558
CrossRef20
Guillermo J. Pons-Estel, Rosa Serrano, Miguel A. Plasín, Gerard Espinosa, Ricard Cervera. (2011) Epidemiology and management of refractory lupus nephritis. Autoimmunity Reviews 10:11, 655-663
CrossRef21
Jan-Eric Turner. (2011) Glomerulonephritis therapy: is there a role for green tea?. Kidney International 80:6, 563-564
CrossRef22
Laurent Arnaud, Noël Zahr, Nathalie Costedoat-Chalumeau, Zahir Amoura. (2011) The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. Autoimmunity Reviews 10:11, 674-678
CrossRef23
Katrina Shum, Anca Askanase. (2011) Treatment of Lupus Nephritis. Current Rheumatology Reports 13:4, 283-290
CrossRef24
Maria Dall’Era, Eliza F. Chakravarty. (2011) Treatment of Mild, Moderate, and Severe Lupus Erythematosus: Focus on New Therapies. Current Rheumatology Reports 13:4, 308-316
CrossRef25
Lisa WiIlcocks, Rachel Jones, David Jayne. (2011) Lupus nephropathy and vasculitis. Medicine 39:8, 486-491
CrossRef26
Adnan N. Kiani, Laurence S. Magder, Michelle Petri. (2011) Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatology International
CrossRef27
Gabriela Schmajuk, Jinoos Yazdany. (2011) Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review. Seminars in Arthritis and Rheumatism 40:6, 559-575
CrossRef28
Karen H. Costenbader, Amrita Desai, Graciela S. Alarcón, Linda T. Hiraki, Tamara Shaykevich, M. Alan Brookhart, Elena Massarotti, Bing Lu, Daniel H. Solomon, Wolfgang C. Winkelmayer. (2011) Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis & Rheumatism 63:6, 1681-1688
CrossRef29
Hitoshi Yokoyama, Hiroshi Okuyama, Hideki Yamaya. (2011) Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians. Clinical and Experimental Nephrology 15:3, 321-330
CrossRef30
Stella Ntali, George Bertsias, Dimitrios T. Boumpas. (2011) Cyclophosphamide and Lupus Nephritis: When, How, For How Long?. Clinical Reviews in Allergy & Immunology 40:3, 181-191
CrossRef31
Christine Hsieh, Anthony Chang, Daniel Brandt, Riteesha Guttikonda, Tammy O. Utset, Marcus R. Clark. (2011) Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care & Research 63:6, 865-874
CrossRef32
Sandeep Singh, Xin J. Zhou, Chul Ahn, Ramesh Saxena. (2011) Lupus Nephritis: A Retrospective Analysis of Clinical Presentation and Outcomes From a Single Center. The American Journal of the Medical Sciences1
CrossRef33
Hala Alshayeb, Barry M. Wall, Elvira O. Gosmanova. (2011) Treatment of Proliferative and Membranous Lupus Nephritis: Review of Key Clinical Trials. The American Journal of the Medical Sciences1
CrossRef34
A. Schwarting. (2011) Nierenbeteiligung beim systemischen Lupus erythematodes. Der Nephrologe 6:3, 258-264
CrossRef35
Y. Mino, T. Naito, K. Shimoyama, N. Ogawa, J. Kawakami. (2011) Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. Journal of Clinical Pharmacy and Therapeuticsno-no
CrossRef36
J. E. Craft. (2011) Dissecting the Immune Cell Mayhem That Drives Lupus Pathogenesis. Science Translational Medicine 3:73, 73ps9-73ps9
CrossRef37
Pietro A.A. Canetta, Gerald B. Appel. (2011) New and emerging treatments for lupus nephritis. Dialysis & Transplantation 40:2, 67-71
CrossRef38
Michelle PETRI. (2011) Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. International Journal of Rheumatic Diseases 14:1, 1-5
CrossRef39
Wei Chen, Xueqing Tang, Qinghua Liu, Weiying Chen, Ping Fu, Fang Liu, Yunhua Liao, Zhenhua Yang, Jinli Zhang, Jian Chen, Tanqi Lou, Junzhou Fu, Yaozhong Kong, Zhengrong Liu, An Fan, Shaoqi Rao, Zhibin Li, Xueqing Yu. (2011) Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial. American Journal of Kidney Diseases 57:2, 235-244
CrossRef40
Vladimir Tesar, Zdenka Hruskova. (2011) Treatment of proliferative lupus nephritis: a slowly changing landscape. Nature Reviews Nephrology 7:2, 96-109
CrossRef41
Norman T. Ilowite, Ronald M. Laxer. 2011. PHARMACOLOGY AND DRUG THERAPY. , 71-126.
CrossRef42
Earl Silverman, Allison Eddy. 2011. SYSTEMIC LUPUS ERYTHEMATOSUS. , 315-343.
CrossRef43
Ramesh Saxena, Tina Mahajan, Chandra Mohan. (2011) Lupus nephritis: current update. Arthritis Research & Therapy 13:5, 240
CrossRef44
Hanns-Martin Lorenz, Wilhelm H Schmitt, Vladimir Tesar, Ulf Müller-Ladner, Ingo Tarner, Ingeborg A Hauser, Falk Hiepe, Tobias Alexander, Heike Woehling, Kyuichi Nemoto, Peter A Heinzel. (2011) Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study. Arthritis Research & Therapy 13:2, R36
CrossRef45
Robert Clancy. 2011. Polymorphonuclear and Endothelial Cells. , 163-175.
CrossRef46
Joan T. Merrill, Kenneth C. Kalunian, Jill P. Buyon. 2011. Design of Clinical Trials for SLE. , 719-726.
CrossRef47
Brad H. Rovin, Isaac E. Stillman. 2011. Kidney. , 769-814.
CrossRef48
Nathalie Costedoat-Chalumeau, Gaëlle Leroux, Jean-Charles Piette, Zahir Amoura. 2011. Antimalarials and SLE. , 1061-1081.
CrossRef49
Surender Rajasekaran, Norma J. Maxvold, Timothy E. Bunchman. 2011. Glomerulotubular Dysfunction and Acute Kidney Injury. , 1016-1035.
CrossRef50
A. L. Hepburn, S. Narat, J. C. Mason. (2010) The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology 49:12, 2243-2254
CrossRef51
D. Soonawala, R. A. Middelburg, M. Egger, J. P. Vandenbroucke, O. M. Dekkers. (2010) Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. International Journal of Epidemiology 39:6, 1567-1581
CrossRef52
J. Cortes-Hernandez, M. T. Torres-Salido, A. S. Medrano, M. V. Tarres, J. Ordi-Ros. (2010) Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrology Dialysis Transplantation 25:12, 3939-3948
CrossRef53
Sebastian Dolff, Jo HM Berden, Marc Bijl. (2010) Treatment of lupus nephritis. Expert Review of Clinical Immunology 6:6, 901-911
CrossRef54
Rebecca Manno, Francesco Boin. (2010) Immunotherapy of systemic sclerosis. Immunotherapy 2:6, 863-878
CrossRef55
J. T. Merrill, R. Burgos-Vargas, R. Westhovens, A. Chalmers, D. D'Cruz, D. J. Wallace, S. C. Bae, L. Sigal, J.-C. Becker, S. Kelly, K. Raghupathi, T. Li, Y. Peng, M. Kinaszczuk, P. Nash. (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 62:10, 3077-3087
CrossRef56
Wai-Johnn Sam, Melanie S Joy. (2010) Population Pharmacokinetics of Mycophenolic Acid and Metabolites in Patients With Glomerulonephritis. Therapeutic Drug Monitoring 32:5, 594-605
CrossRef57
Antoni Sisó, Manuel Ramos-Casals, Albert Bové, Pilar Brito-Zerón, Natalia Soria, Norma Nardi, Adriana Testi, Marta Perez-de-Lis, Cándido Díaz-Lagares, Alejandro Darnell, Juan Sentís, Antonio Coca. (2010) Outcomes in Biopsy-Proven Lupus Nephritis. Medicine 89:5, 300-307
CrossRef58
Paungpaga Lertdumrongluk, Poorichaya Somparn, Wonngarm Kittanamongkolchai, Opas Traitanon, Somratai Vadcharavivad, Yingyos Avihingsanon. (2010) Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney International 78:4, 389-395
CrossRef59
K. Dalton, M. Smith, J. M. Thurman. (2010) The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease. NDT Plus 3:4, 346-348
CrossRef60
David E Leaf, Gerald B Appel, Jai Radhakrishnan. (2010) Glomerular disease: why is there a dearth of high quality clinical trials?. Kidney International 78:4, 337-342
CrossRef61
Tomasz Pawinski. (2010) Therapeutic drug monitoring of mycophenolic acid: a potential treatment for lupus nephritis. Kidney International 78:4, 335-336
CrossRef62
Sibylle von Vietinghoff, Hui Ouyang, Klaus Ley. (2010) Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production. Kidney International 78:1, 79-88
CrossRef63
Stephen D Marks, Kjell Tullus. (2010) Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatrica 99:7, 967-974
CrossRef64
Meng-Yu Weng, Chia-Tse Weng, Ming-Fei Liu. (2010) The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clinical Rheumatology 29:7, 771-775
CrossRef65
Nanticha Kamanamool, Mark McEvoy, John Attia, Atiporn Ingsathit, Pintip Ngamjanyaporn, Ammarin Thakkinstian. (2010) Efficacy and Adverse Events of Mycophenolate Mofetil Versus Cyclophosphamide for Induction Therapy of Lupus Nephritis. Medicine 89:4, 227-235
CrossRef66
Kavita G. Sharma, Raju Radha, Andy Pao, Nurmamet Amet, Lara Baden, Stanley C. Jordan, Mieko Toyoda. (2010) Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transplant Immunology 23:3, 117-120
CrossRef67
Feng Yu, Li-hua Wu, Ying Tan, Li-hua Li, Cai-li Wang, Wen-ke Wang, Zhen Qu, Meng-hua Chen, Jun-jie Gao, Zeng-yan Li, Xin Zheng, Jie Ao, Sai-nan Zhu, Su-xia Wang, Ming-hui Zhao, Wan-zhong Zou, Gang Liu. (2010) Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney International 77:9, 820-829
CrossRef68
Liz Lightstone. (2010) Lupus nephritis: where are we now?. Current Opinion in Rheumatology 22:3, 252-256
CrossRef69
Daniel Elbirt, Dalia Sthoeger, Ilan Asher, Zev Moshe Sthoeger. (2010) The management of systemic lupus erythematosus: Facts and controversies. Clinics in Dermatology 28:3, 330-336
CrossRef70
K. Thürmel. (2010) Induktionstherapie bei Lupusnephritis. Der Nephrologe 5:2, 150-151
CrossRef71
Robert Clancy, Ellen M. Ginzler. (2010) Endothelial Function and its Implications for Cardiovascular and Renal Disease in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America 36:1, 145-160
CrossRef72
Gunnar Brandhorst, Franziska Brehmer, Darinka T Petrova, Oliver Gross, Nicolai Miosge, Victor W Armstrong, Michael Oellerich. (2010) Mycophenolic Acid Predose Concentrations and Renal Function in a Mouse Model for Progressive Renal Fibrosis. Therapeutic Drug Monitoring 32:1, 73-78
CrossRef73
D. J. Hobbs, G.-M. Barletta, J. S. Rajpal, M. N. Rajpal, D. P. Weismantel, J. D. Birmingham, T. E. Bunchman. (2010) Severe paediatric systemic lupus erythematosus nephritis--a single-centre experience. Nephrology Dialysis Transplantation 25:2, 457-463
CrossRef74
Jai Radhakrishnan, Dimitrios-Anestis Moutzouris, Ellen M Ginzler, Neil Solomons, Ilias I Siempos, Gerald B Appel. (2010) Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney International 77:2, 152-160
CrossRef75
Sandra V. Navarra, Oscar D. Naidas. 2010. Management of Systemic Lupus Erythematosus Renal Disease. , 108-123.
CrossRef76
Ellen M. Ginzler, David Wofsy, David Isenberg, Caroline Gordon, Laura Lisk, Mary-Anne Dooley, . (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis & Rheumatism 62:1, 211-221
CrossRef77
Esra Baskin, Seza Ozen, Nilgun Çakar, Umut S. Bayrakci, Erkan Demirkaya, Aysin Bakkaloglu. (2010) The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis. Pediatric Nephrology 25:1, 111-117
CrossRef78
Joan F. Hilton. (2010) Noninferiority trial designs for odds ratios and risk differences. Statistics in Medicinen/a-n/a
CrossRef79
Paul A. Monach, Lindsay M. Arnold, Peter A. Merkel. (2010) Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data-driven review. Arthritis & Rheumatism 62:1, 9-21
CrossRef80
Dawn M. Wahezi, Norman T. Ilowite. 2010. Management of the Connective Tissue Diseases of Childhood. , 249-274.
CrossRef81
Takafumi NAITO. (2010) Optimal Immunosuppressive Therapy Based on Pharmacokinetics and Pharmacodynamics of Antimetabolites in Clinical Practice. YAKUGAKU ZASSHI 130:12, 1695-1700
CrossRef82
D. Isenberg, G. B. Appel, G. Contreras, M. A. Dooley, E. M. Ginzler, D. Jayne, J. Sanchez-Guerrero, D. Wofsy, X. Yu, N. Solomons. (2010) Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49:1, 128-140
CrossRef83
F. Yu, Y. Tan, M.-H. Zhao. (2010) Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome. Nephrology Dialysis Transplantation 25:1, 145-152
CrossRef84
Nobuyuki Miyasaka, Shinichi Kawai, Hiroshi Hashimoto. (2009) Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Modern Rheumatology 19:6, 606-615
CrossRef85
G. Martini, A. V. Ramanan, F. Falcini, H. Girschick, D. P. Goldsmith, F. Zulian. (2009) Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology 48:11, 1410-1413
CrossRef86
Sabha Bhatti, Abdul Hakeem, Jose Torrealba, Joseph P. McMahon, Keith C. Meyer. (2009) Severe acute fibrinous and organizing pneumonia (AFOP) causing ventilatory failure: Successful treatment with mycophenolate mofetil and corticosteroids. Respiratory Medicine 103:11, 1764-1767
CrossRef87
Baptiste Hervier, Agathe Masseau, Jean-Marie Mussini, Marie Audrain, Mohamed A. Hamidou. (2009) Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine 76:5, 575-576
CrossRef88
Giovanna Cuomo, Giuseppina Abignano, Gabriele Valentini. (2009) Early onset neutropenia after mycophenolate mofetil in systemic sclerosis. Rheumatology International 29:12, 1529-1530
CrossRef89
C. Molino, F. Fabbian, C. Longhini. (2009) Clinical approach to lupus nephritis: Recent advances. European Journal of Internal Medicine 20:5, 447-453
CrossRef90
Brad H. Rovin. (2009) Glomerular disease: Lupus nephritis treatment: are we beyond cyclophosphamide?. Nature Reviews Nephrology 5:9, 492-494
CrossRef91
Styliani Ntali, Michail Tzanakakis, George Bertsias, Dimitrios T Boumpas. (2009) What’s new in clinical trials in lupus?. International Journal of Clinical Rheumatology 4:4, 473-485
CrossRef92
Andrew S. Levey, Daniel Cattran, Aaron Friedman, W. Greg Miller, John Sedor, Katherine Tuttle, Bertram Kasiske, Thomas Hostetter. (2009) Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration. American Journal of Kidney Diseases 54:2, 205-226
CrossRef93
Feng Yu, Ying Tan, Gang Liu, Su-xia Wang, Wan-zhong Zou, Ming-hui Zhao. (2009) Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney International 76:3, 307-317
CrossRef94
Jennifer M. Grossman. (2009) Lupus arthritis. Best Practice & Research Clinical Rheumatology 23:4, 495-506
CrossRef95
A. Mak, A. A. C. Cheak, J. Y. S. Tan, H. C. Su, R. C. M. Ho, C. S. Lau. (2009) Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology 48:8, 944-952
CrossRef96
Keisha L. Gibson, Debbie S. Gipson, Susan F. Massengill. (2009) Renal Manifestations of Systemic Illness in Children. Seminars in Nephrology 29:4, 360-369
CrossRef97
Susan Yung, Qing Zhang, Chen Zhu Zhang, Kwok Wah Chan, Sing Leung Lui, Tak Mao Chan. (2009) Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis & Rheumatism 60:7, 2071-2082
CrossRef98
J. N. Boletis, S. Marinaki, C. Skalioti, S. S. Lionaki, A. Iniotaki, P. P. Sfikakis. (2009) Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrology Dialysis Transplantation 24:7, 2157-2160
CrossRef99
Kenneth Kalunian, T. Merrill Joan. (2009) New directions in the treatment of systemic lupus erythematosus. Current Medical Research and Opinion 25:6, 1501-1514
CrossRef100
Maria Dall'Era, David Wofsy. (2009) Systemic lupus erythematosus clinical trials—an interim analysis. Nature Reviews Rheumatology 5:6, 348-351
CrossRef101
Mohammad Hassan Moradinejad. (2009) Treatment of intractable pulmonary hemorrhage in two patients with childhood systemic lupus erythematosus. Rheumatology International 29:9, 1113-1115
CrossRef102
Sandeep Singh, Ramesh Saxena. (2009) Lupus Nephritis. The American Journal of the Medical Sciences 337:6, 451-460
CrossRef103
Rachel B Jones, Michael Walsh, Kenneth GC Smith. (2009) What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?. Current Opinion in Rheumatology 21:3, 256-261
CrossRef104
Robert Eisenberg. (2009) Why can't we find a new treatment for SLE?. Journal of Autoimmunity 32:3-4, 223-230
CrossRef105
Chi Chiu Mok. (2009) Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nature Reviews Nephrology 5:4, 212-220
CrossRef106
Alice S Appel, Gerald B Appel. (2009) An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nature Clinical Practice Nephrology 5:3, 132-142
CrossRef107
M. Y. Karim, C. N. Pisoni, M. A. Khamashta. (2009) Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not!. Rheumatology 48:4, 332-341
CrossRef108
Mirhelen Mendes De Abreu, Amiran Gafni, Marcos Bosi Ferraz. (2009) Development and testing of a decision board to help clinicians present treatment options to lupus nephritis patients in Brazil. Arthritis Care & Research 61:1, 37-45
CrossRef109
Melanie S Joy, Tandrea Hilliard, Yichun Hu, Susan L Hogan, Mary Anne Dooley, Ronald J Falk, Philip C Smith. (2009) Pharmacokinetics of Mycophenolic Acid in Patients with Lupus Nephritis. Pharmacotherapy 29:1, 7-16
CrossRef110
Daisuke SUZUKI, Noriyoshi OGAWA, Jin SAWADA, Osamu KIMOTO, Kumiko SHIMOYAMA, Hideharu HAYASHI. (2009) The efficacy of mycophenolate mofetil for systemic lupus erythematosus. Japanese Journal of Clinical Immunology 32:4, 263-268
CrossRef111
A. Smyth, V. D. Garovic. (2009) 25-Year-Old Man With Flank Pain, Hematuria, and Proteinuria. Mayo Clinic Proceedings 84:1, 72-75
CrossRef112
P. M. Izmirly, L. Barisoni, J. P. Buyon, M. Y. Kim, T. L. Rivera, J. S. Schwartzman, J. M. Weisstuch, D. T. Liu, S. Bernstein, C.-E. Tseng, H. M. Belmont, C. T. Esmon, J. T. Merrill, A. D. Askanase, D. B. Thomas, R. M. Clancy. (2008) Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology 48:5, 513-519
CrossRef113
Yasuaki Mino, Takafumi Naito, Tomomi Matsushita, Atsushi Otsuka, Tomomi Ushiyama, Seiichiro Ozono, Akira Hishida, Yoshiyuki Kagawa, Junichi Kawakami. (2008) Comparison of Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Between Patients With Lupus Nephritis and With Kidney Transplantation. Therapeutic Drug Monitoring 30:6, 656-661
CrossRef114
J. M. Bargman. (2008) How did cyclophosphamide become the drug of choice for lupus nephritis?. Nephrology Dialysis Transplantation 24:2, 381-384
CrossRef115
S. M. Benseler, J. M. Bargman, B. M. Feldman, P. N. Tyrrell, E. Harvey, D. Hebert, E. D. Silverman. (2008) Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome. Rheumatology 48:2, 176-182
CrossRef116
B. C. M. de Winter, T. van Gelder. (2008) Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases. Nephrology Dialysis Transplantation 23:11, 3386-3388
CrossRef117
I. Neumann, H. Fuhrmann, I-F. Fang, A. Jaeger, P. Bayer, J. Kovarik. (2008) Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrology Dialysis Transplantation 23:11, 3514-3520
CrossRef118
A. Schwarting. (2008) Die Nierenbeteiligung beim systemischen Lupus erythematodes. Der Nephrologe 3:6, 471-475
CrossRef119
Deepak Gupta, Anita Zachariah, Heidi Roppelt, Aarat M. Patel, Barry L. Gruber. (2008) Prophylactic Antibiotic Usage for Pneumocystis jirovecii Pneumonia in Patients With Systemic Lupus Erythematosus on Cyclophosphamide. JCR: Journal of Clinical Rheumatology 14:5, 267-272
CrossRef120
David Philibert, Daniel Cattran. (2008) Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price?. Nature Clinical Practice Nephrology 4:10, 550-559
CrossRef121
N. Costedoat-Chalumeau, G. Leroux, Z. Amoura, J.-C. Piette. (2008) Hydroxychloroquine dans le traitement du lupus: le renouveau. La Revue de Médecine Interne 29:9, 735-737
CrossRef122
E. Daugas. (2008) Traitement des glomérulonéphrites lupiques prolifératives. Évolution des idées et situation en 2008. La Revue de Médecine Interne 29:9, 710-717
CrossRef123
Z. Amoura. (2008) Le lupus systémique de 1968 à 2008 : la révolution silencieuse. La Revue de Médecine Interne 29:9, 689-690
CrossRef124
Thai Nguyen, Robert D. Toto. (2008) Slowing chronic kidney disease progression: results of prospective clinical trials in adults. Pediatric Nephrology 23:9, 1409-1422
CrossRef125
Sofie P.M. Janssen, Marko Phernambucq, Pilar Martinez-Martinez, Marc H. De Baets, Mario Losen. (2008) Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. Journal of Neuroimmunology 201-202, 111-120
CrossRef126
Laurent Camous, Catherine Melander, Marion Vallet, Tarek Squalli, Bertrand Knebelmann, Laure-Hélène Noël, Fadi Fakhouri. (2008) Complete Remission of Lupus Nephritis With Rituximab and Steroids for Induction and Rituximab Alone for Maintenance Therapy. American Journal of Kidney Diseases 52:2, 346-352
CrossRef127
Shang-Yu Huang, Ho-Yen Chueh, Sheng-Wen Shaw, Jin-Chung Shih, Po-Jen Cheng. (2008) Sonographic diagnosis of fetal malformations associated with mycophenolate mofetil exposure in utero. American Journal of Obstetrics and Gynecology 199:2, e6-e8
CrossRef128
Garyfallia Perysinaki, Simeon Panagiotakis, George Bertsias, Dimitrios T Boumpas. (2008) Pharmacotherapy of lupus nephritis: time for a consensus?. Expert Opinion on Pharmacotherapy 9:12, 2099-2115
CrossRef129
Jian Wang, Michael Figurski, Leslie M. Shaw, Gilbert J. Burckart. (2008) The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transplant Immunology 19:3-4, 192-196
CrossRef130
Martin Aringer, Josef S Smolen. (2008) Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opinion on Drug Safety 7:4, 411-419
CrossRef131
Michelle Petri, Nuntana Kasitanon, Shin-Seok Lee, Kimberly Link, Laurence Magder, Sang-Cheol Bae, John G. Hanly, David A. Isenberg, Ola Nived, Gunnar Sturfelt, Ronald van Vollenhoven, Daniel J. Wallace, Graciela S. Alarcón, Dwomoa Adu, Carmen Avila-Casado, Sasha R. Bernatsky, Ian N. Bruce, Ann E. Clarke, Gabriel Contreras, Derek M. Fine, Dafna D. Gladman, Caroline Gordon, Kenneth C. Kalunian, Michael P. Madaio, Brad H. Rovin, Jorge Sanchez-Guerrero, Kristjan Steinsson, Cynthia Aranow, James E. Balow, Jill P. Buyon, Ellen M. Ginzler, Munther A. Khamashta, Murray B. Urowitz, Mary Anne Dooley, Joan T. Merrill, Rosalind Ramsey-Goldman, Josef Font, James Tumlin, Thomas Stoll, Asad Zoma, . (2008) Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index. Arthritis & Rheumatism 58:6, 1784-1788
CrossRef132
&NA;. (2008) Early detection and individualized treatment of elderly-onset systemic lupus erythematosus optimizes symptom control. Drugs & Therapy Perspectives 24:6, 13
CrossRef133
Michelle Petri, Nuntana Kasitanon, Sukminder Singh, Kimberly Link, Laurence Magder, Sang-Cheol Bae, John G. Hanly, Ola Nived, Gunnar Sturfelt, Ronald van Vollenhoven, Daniel J. Wallace, Graciela S. Alarcón, Dwomoa Adu, Carmen Avila-Casado, Sasha R. Bernatsky, Ian N. Bruce, Ann E. Clarke, Gabriel Contreras, Derek M. Fine, Dafna D. Gladman, Caroline Gordon, Kenneth C. Kalunian, Michael P. Madaio, Brad H. Rovin, Jorge Sanchez-Guerrero, Kristjan Steinsson, Cynthia Aranow, James E. Balow, Jill P. Buyon, Ellen M. Ginzler, Munther A. Khamashta, Murray B. Urowitz, Mary Anne Dooley, Joan T. Merrill, Rosalind Ramsey-Goldman, Josef Font, James Tumlin, Thomas Stoll, Asad Zoma, . (2008) Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response. Arthritis & Rheumatism 58:6, 1789-1795
CrossRef134
Ewa Olech, Joan T Merrill. (2008) Mycophenolate mofetil for lupus nephritis. Expert Review of Clinical Immunology 4:3, 313-319
CrossRef135
Cecilia N Pisoni, David P D'Cruz. (2008) The safety of mycophenolate mofetil in pregnancy. Expert Opinion on Drug Safety 7:3, 219-222
CrossRef136
J Wang, JW Yang, A Zeevi, SA Webber, DM Girnita, R Selby, J Fu, T Shah, V Pravica, IV Hutchinson, GJ Burckart. (2008) IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients. Clinical Pharmacology & Therapeutics 83:5, 711-717
CrossRef137
J. Lv, H. Zhang, Z. Cui, T. Su, Y. Zhang, H. Wang. (2008) Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrology Dialysis Transplantation 23:9, 2868-2872
CrossRef138
Marion Haubitz. (2008) Is individualized therapy the future of lupus treatment?. Future Rheumatology 3:2, 143-151
CrossRef139
Irmgard Neumann, Heinz Fuhrmann, Marina Kanzler, I-Fei Fang, Adelheid Jaeger, Helmut Graf, Peter Bayer, Josef Kovarik. (2008) Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. Expert Opinion on Pharmacotherapy 9:6, 879-886
CrossRef140
L. Silva-Fernández, J.L. Andreu-Sánchez, E.M. Ginzler. (2008) Current therapy of lupus nephritis. Which is the best option?. Revista Clínica Española 208:3, 138-141
CrossRef141
Obioma Nwobi, Carolyn L. Abitbol, Jayanthi Chandar, Wacharee Seeherunvong, Gastón Zilleruelo. (2008) Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatric Nephrology 23:3, 413-419
CrossRef142
Arrigo Schieppati, Giuseppe Remuzzi. (2008) Novel therapies of lupus nephritis. Current Opinion in Nephrology and Hypertension 17:2, 156-161
CrossRef143
P Bhat, J Radhakrishnan. (2008) B lymphocytes and lupus nephritis: New insights into pathogenesis and targeted therapies. Kidney International 73:3, 261-268
CrossRef144
Laurent Sailler. (2008) Rituximab Off Label Use for Difficult-To-Treat Auto-Immune Diseases: Reappraisal of Benefits and Risks. Clinical Reviews in Allergy & Immunology 34:1, 103-110
CrossRef145
Ana C. Zamora, Paul J. Wolters, Harold R. Collard, M. Kari Connolly, Brett M. Elicker, W. Richard Webb, Talmadge E. King, Jeffrey A. Golden. (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respiratory Medicine 102:1, 150-155
CrossRef146
Sankar D Navaneethan, Gautham Viswanathan, Giovanni F M Strippoli. (2008) Treatment Options for Proliferative Lupus Nephritis. Drugs 68:15, 2095-2104
CrossRef147
Jose Maria Pego-Reigosa, David A Isenberg. (2008) Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. Expert Opinion on Investigational Drugs 17:1, 31-41
CrossRef148
Alice Sue Appel, Gerald B. Appel. 2008. Immunosuppressive Agents for the Therapy of Glomerular and Tubulointerstitial Disease. , 105-111.
CrossRef149
James E. Balow, Meryl Waldman, Howard A. Austin. 2008. Lupus Nephritis. , 157-171.
CrossRef150
Noël Zahr, Zahir Amoura, Jean Debord, Jean-Sébastien Hulot, Franck Saint-Marcoux, Pierre Marquet, Jean Charles Piette, Philippe Lechat. (2008) Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies. Clinical Pharmacokinetics 47:4, 277-284
CrossRef151
James E. Balow, Monique E. Cho, Howard A. Austin. 2008. Immunologic renal diseases. , 995-1012.
CrossRef152
M KAZDEROVA, E JANCOVA, R RYSAVA, M MERTA, V TESAR. (2008) Mycophenolate Mofetil in Low Doses Stabilizes and Improves Antineutrophil Cytoplasmic Antibody-associated Vasculitis and Lupus Nephritis. Archives of Medical Research 39:1, 115-119
CrossRef153
Lucía Silva Fernández, José Luis Andréu Sánchez, Ellen M. Ginzler. (2008) Treatment of Lupus Nephritis. Reumatolog ía Cl ínica (English Edition) 4:4, 140-151
CrossRef154
F.A. Houssiau. (2007) Néphropathie du lupus. La Revue de Médecine Interne 28, S304-S305
CrossRef155
J. Ermann, B. L. Bermas. (2007) The biology behind the new therapies for SLE. International Journal of Clinical Practice 61:12, 2113-2119
CrossRef156
R. Fischer-Betz, M. Schneider. (2007) ModerneTherapie bei systemischem Lupus erythematodes. Zeitschrift für Rheumatologie 66:8, 662-671
CrossRef157
(2007) Therapieempfehlung zur Lupusnephritis bei Kindern und Jugendlichen. Monatsschrift Kinderheilkunde 155:12, 1175-1188
CrossRef158
G. Espinosa Garriga, R. Cervera Segura. (2007) Nuevos conceptos en el tratamiento de la nefropatía lúpica. Revista Clínica Española 207:11, 570-572
CrossRef159
Jennifer K. King, Bevra H. Hahn. (2007) Systemic lupus erythematosus: modern strategies for management – a moving target. Best Practice & Research Clinical Rheumatology 21:6, 971-987
CrossRef160
Chi Chiu Mok. (2007) Management of systemic lupus erythematosus in Chinese patients. Expert Review of Clinical Immunology 3:6, 925-935
CrossRef161
Y. Le Meur, M. Büchler, A. Thierry, S. Caillard, F. Villemain, S. Lavaud, I. Etienne, P.-F. Westeel, B. H. de Ligny, L. Rostaing, E. Thervet, J. C. Szelag, J.-P. Rérolle, A. Rousseau, G. Touchard, P. Marquet. (2007) Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation. American Journal of Transplantation 7:11, 2496-2503
CrossRef162
Bertrand Godeau, Drew Provan, James Bussel. (2007) Immune thrombocytopenic purpura in adults. Current Opinion in Hematology 14:5, 535-556
CrossRef163
Ana Paredes. (2007) Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis?. Pediatric Nephrology 22:8, 1077-1082
CrossRef164
L.T. Weber. (2007) Verbesserung der Arzneimittelsicherheit durch Therapiemonitoring. Monatsschrift Kinderheilkunde 155:8, 724-732
CrossRef165
Susanne M. Benseler, Earl D. Silverman. (2007) Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America 33:3, 471-498
CrossRef166
2007. Emerging Therapies to Treat Lupus Erythematosus. .
CrossRef167
Lionel Couzi, Pierre Merville, Colette Deminière, Jean-François Moreau, Christian Combe, Jean-Luc Pellegrin, Jean-François Viallard, Patrick Blanco. (2007) Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis. Arthritis & Rheumatism 56:7, 2362-2370
CrossRef168
H. Nunes, Y. Uzunhan. (2007) Le mycophénolate mofétil semble stabiliser la fonction respiratoire dans les pneumopathies interstitielles associées aux connectivites. Revue des Maladies Respiratoires 24, 137-138
CrossRef169
Iva Gunnarsson, Birgitta Sundelin, Thorunn Jónsdóttir, Stefan H. Jacobson, Elisabet Welin Henriksson, Ronald F. van Vollenhoven. (2007) Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis & Rheumatism 56:4, 1263-1272
CrossRef170
Jian Wang, Adriana Zeevi, Steve Webber, Diana M. Girnita, Linda Addonizio, Rick Selby, Ian V. Hutchinson, Gilbert J. Burckart. (2007) A novel variant L263F in human inosine 5???-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenetics and Genomics 17:4, 283-290
CrossRef171
Tak Mao Chan. (2007) Histologic deterioration and more flares: The case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis. Arthritis & Rheumatism 56:3, 702-704
CrossRef172
R. Fischer-Betz, F. Hiepe. (2007) Neufassung der Empfehlungen der Kommission Pharmakotherapie der DGRh. Zeitschrift für Rheumatologie 66:1, 78-82
CrossRef173
Earl Silverman. (2007) Pediatric systemic lupus erythematosus. Future Rheumatology 2:1, 23-50
CrossRef174
Irina Buhaescu, Adrian Covic, Gilbert Deray. (2007) Treatment of Proliferative Lupus Nephritis—A Critical Approach. Seminars in Arthritis and Rheumatism 36:4, 224-237
CrossRef175
Luca Iaccarino, Mariaelisa Rampudda, Mariagrazia Canova, Sara Della Libera, Piercarlo Sarzi-Puttinic, Andrea Doria. (2007) Mycophenolate mofetil: What is its place in the treatment of autoimmune rheumatic diseases?. Autoimmunity Reviews 6:3, 190-195
CrossRef176
Mary Anne Dooley, Ronald J. Falk. (2007) Human Clinical Trials in Lupus Nephritis. Seminars in Nephrology 27:1, 115-127
CrossRef177
A. Schwarting. (2007) Lupusnephritis. Der Nephrologe 2:1, 33-36
CrossRef178
Deana Lazaro. (2007) Elderly-Onset Systemic Lupus Erythematosus. Drugs & Aging 24:9, 701-715
CrossRef179
Tak Mao CHAN. (2006) Mycophenolate mofetil in the treatment of lupus nephritis: an appraisal of recent data. APLAR Journal of Rheumatology 9:4, 403-407
CrossRef180
Paul Hasler, Moncef Zouali. (2006) B lymphocytes as therapeutic targets in systemic lupus erythematosus. Expert Opinion on Therapeutic Targets 10:6, 803-815
CrossRef181
C. C. MOK. (2006) Update on the current therapies of lupus nephritis. APLAR Journal of Rheumatology 9:4, 397-402
CrossRef182
G B Appel, M Waldman, J Radhakrishnan. (2006) New approaches to the treatment of glomerular diseases. Kidney International 70, S45-S50
CrossRef183
Hiok Hee CHNG. (2006) Management of systemic lupus erythematosus in the coming decade: potentials and challenges. APLAR Journal of Rheumatology 9:4, 419-424
CrossRef184
Jean Sibilia. (2006) Treatment of systemic lupus erythematosus in 2006. Joint Bone Spine 73:6, 591-598
CrossRef185
Anne Davidson, Cynthia Aranow. (2006) Pathogenesis and treatment of systemic lupus erythematosus nephritis. Current Opinion in Internal Medicine 5:6, 631-638
CrossRef186
Graciela S. Alarcón. (2006) Infections in Systemic Connective Tissue Diseases: Systemic Lupus Erythematosus, Scleroderma, and Polymyositis/Dermatomyositis. Infectious Disease Clinics of North America 20:4, 849-875
CrossRef187
Chi Chiu Mok. (2006) Emerging drug therapies for systemic lupus erythematosus. Expert Opinion on Emerging Drugs 11:4, 597-608
CrossRef188
Pantelis Panopalis, Ann E Clarke. (2006) Systemic lupus erythematosus: clinical manifestations, treatment and economics. Expert Review of Pharmacoeconomics & Outcomes Research 6:5, 563-575
CrossRef189
M Waldman, G B Appel. (2006) Update on the treatment of lupus nephritis. Kidney International 70:8, 1403-1412
CrossRef190
Chi Chiu Mok. (2006) Therapeutic Options for Resistant Lupus Nephritis. Seminars in Arthritis and Rheumatism 36:2, 71-81
CrossRef191
Maria DallʼEra, David Wofsy. (2006) Clinical trial design in systemic lupus erythematosus. Current Opinion in Rheumatology 18:5, 476-480
CrossRef192
Ioana Moldovan. (2006) Systemic lupus erythematosus Current state of diagnosis and treatment. Comprehensive Therapy 32:3, 158-162
CrossRef193
Christiane Schneider-Gold, Hans-Peter Hartung, Ralf Gold. (2006) Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases. Muscle & Nerve 34:3, 284-291
CrossRef194
C Grootscholten, G Ligtenberg, E C Hagen, A W L van den Wall Bake, J W de Glas-Vos, M Bijl, K J Assmann, J A Bruijn, J J Weening, H C van Houwelingen, R H W M Derksen, J H M Berden. (2006) Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney International 70:4, 732-742
CrossRef195
D Adu. (2006) Treatment of proliferative lupus nephritis: a changing landscape. Kidney International 70:4, 616-618
CrossRef196
Titte R Srinivas, Jesse D Schold, Herwig-Ulf Meier-Kriesche. (2006) Mycophenolate mofetil: long-term outcomes in solid organ transplantation. Expert Review of Clinical Immunology 2:4, 495-518
CrossRef197
Jennifer R Elliott, Susan Manzi. (2006) Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide. Nature Clinical Practice Rheumatology 2:7, 354-355
CrossRef198
Ana M Arango, John D Reveille. (2006) Update on the treatment of systemic lupus erythematosus. Women's Health 2:4, 605-616
CrossRef199
Phillip Scheinberg, Olga Nunez, Colin Wu, Neal S. Young. (2006) Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. British Journal of Haematology 133:6, 606-611
CrossRef200
Christian Burchardi, Detlef Schlöndorff. (2006) Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide. Nature Clinical Practice Nephrology 2:6, 314-315
CrossRef201
G B Appel, M Waldman. (2006) The IgA nephropathy treatment dilemma. Kidney International 69:11, 1939-1944
CrossRef202
Arvind Kaul, David D'Cruz, Graham RV Hughes. (2006) New therapies for systemic lupus erythematosus: has the future arrived?. Future Rheumatology 1:2, 235-247
CrossRef203
C. C. MOK. (2006) Therapeutic advances in systemic lupus erythematosus. APLAR Journal of Rheumatology 9:1, 18-23
CrossRef204
M. Aringer, J. S. Smolen. (2006) Systemischer Lupus erythematodes: Aktivität und Outcome. Zeitschrift für Rheumatologie 65:2, 103-109
CrossRef205
Reinier M van Hest, Dennis A Hesselink, Arnold G Vulto, Ron AA Mathot, Teun van Gelder. (2006) Individualisation of mycophenolate mofetil dose in renal transplant recipients. Expert Opinion on Pharmacotherapy 7:4, 361-376
CrossRef206
(2006) Mycophenolate Mofetil or Intravenous Cyclophosphamide in Lupus Nephritis. New England Journal of Medicine 354:7, 764-765
Full Text207
(2006) Journal club. Kidney International 69:3, 428-429
CrossRef208
Mary Anne Dooley, Ellen M. Ginzler. (2006) Newer Therapeutic Approaches for Systemic Lupus Erythematosus: Immunosuppressive Agents. Rheumatic Disease Clinics of North America 32:1, 91-102
CrossRef209
Daniel J Wallace. (2006) Is mycophenolate mofetil a safe and effective treatment for patients with systemic lupus erythematosus?. Nature Clinical Practice Rheumatology 2:1, 16-17
CrossRef210
K HAMMERSMITH. (2006) Mycophenolate Mofetil Therapy for Inflammatory Eye DiseaseThorne JE, Jabs DA, Qazi FA, et al (Johns Hopkins Univ, Baltimore, Md; Royal Preston Hosp, England) Ophthalmology 112:1472–1477, 2005§. Yearbook of Ophthalmology 2006, 103-105
CrossRef211
McCune, W. Joseph, . (2005) Mycophenolate Mofetil for Lupus Nephritis. New England Journal of Medicine 353:21, 2282-2284
Full Text
- Letters
